2026-04-13T04:13:42Zhttps://recercat.cat/oai/requestoai:recercat.cat:11351/124222025-10-24T10:40:30Zcom_2072_378070com_2072_378040col_2072_378092
RECERCAT
author
YUSTE GUTIERREZ, ANGEL MANUEL
author
Alonso Moreno, Marta
author
Perez Blanco, Jose Luis
author
Peña Fernandez, Maria Angeles
author
Perez Maroto, Maria Teresa
author
David, Berlana
2025-10-24T10:40:30Z
2025-10-24T10:40:30Z
2025-01-16T08:42:50Z2025-01-16T08:42:50Z2024-11-16
http://hdl.handle.net/11351/12422
Ferric carboxymaltose; Iron deficiency anemia; Iron intravenous administrationCarboximaltosa férrica; Anemia ferropénica; Administración intravenosa de hierroCarboximaltosa fèrrica; Anèmia ferropènica; Administració intravenosa de ferroAim: Anemia, primarily due to iron deficiency, is a key risk factor in both elective and emergency surgeries. Immediate preoperative treatment with ferric carboxymaltose (FCM) in anemic patients can reduce the need for transfusions and the length of hospital stay, thereby optimizing surgical outcomes. The objective of this study was to assess the effectiveness and describe the use of administering intravenous FCM prior to elective scheduled surgery for patients diagnosed with anemia.
Methods: Multicenter, retrospective cohort study that encompassed patients aged 18 years and older who underwent surgery between January 2017 and December 2018. Demographic variables, dose scheme, baseline and perioperative haemoglobin (Hb), transfusion requirements, and admission days were collected. The primary endpoints were the response rate and effectiveness of FCM, defined as the proportion of patients with Hb preoperative levels of ≥ 13 g/dL. A patient response was deemed to occur when Hb level increased by 1 g/dL or more. The secondary endpoints were the appropriateness of FCM dose, transfusion requirement rate, and length of hospital stay.
Results: 446 patients (55.2% women, median age 69 IQR:52– 78 years) were included. The median total dose of FCM administered was 1000 mg over a span of 5 day (IQR: 0– 16) days before surgery. 62.8% of patients received lower doses, 24.9% had an INCREASE of Hb ≥ 1 g/dL, 11.6% had Hb ≥ 13 g/dL and 21.3% required blood transfusions, with a mean of 0.73 units transfused. The length of the hospital stay was 12 days (IQR:6– 23).
Conclusion: Low percentage of patients achieved a hemoglobin level of 13 g/dL or experienced an increase in hemoglobin of 1 g/dL or more following the administration of FCM, indicating the low effectiveness of FCM in treating perioperative anaemia in our surgical patients. There is underdosing of FCM and insufficient time between FCM administration and surgery in most patients. Both transfused and non-transfused patients show similar Hb increases, while those receiving a standard 1000 mg dose of FCM experience shorter hospital stays compared to those receiving 500 mg, and patients with more transfusions have longer hospital stays.
Attribution-NonCommercial 4.0 International http://creativecommons.org/licenses/by-nc/4.0/ info:eu-repo/semantics/openAccess
Anèmia ferropènica - Tractament
Ferro - Ús terapèutic
Cirurgia - Complicacions
Avaluació de resultats (Assistència sanitària)
DISEASES::Hemic and Lymphatic Diseases::Hematologic Diseases::Anemia::Anemia, Hypochromic::Anemia, Iron-Deficiency
Other subheadings::Other subheadings::Other subheadings::/drug therapy
CHEMICALS AND DRUGS::Inorganic Chemicals::Elements::Metals, Heavy::Iron
Other subheadings::Other subheadings::/therapeutic use
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Probability::Risk::Risk Factors
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Patient Care::Perioperative Care
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis::Treatment Outcome
ENFERMEDADES::enfermedades hematológicas y linfáticas::enfermedades hematológicas::anemia::anemia hipocrómica::anemia ferropénica
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
COMPUESTOS QUÍMICOS Y DROGAS::compuestos inorgánicos::elementos::metales pesados::hierro
Otros calificadores::Otros calificadores::/uso terapéutico
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::técnicas de investigación::métodos epidemiológicos::estadística como asunto::probabilidad::riesgo::factores de riesgo
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::asistencia al paciente::asistencia periquirúrgica
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico::resultado del tratamiento
Use and Effectiveness of Carboximaltose Iron in Preoperative Anemia Treatment: A Multicenter and Retrospective Study
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion